50 likes | 233 Views
The LIFE Trial. Losartan Intervention For Endpoint reduction in hypertension study (LIFE) Presented at the American College of Cardiology 51st Annual Scientific Session Atlanta, GA Dr Björn Dahlöf for the LIFE Investigators. LIFE: Study Design.
E N D
The LIFE Trial Losartan Intervention For Endpoint reduction in hypertension study (LIFE) Presented at theAmerican College of Cardiology 51st Annual Scientific Session Atlanta, GA Dr Björn Dahlöf for the LIFE Investigators
LIFE: Study Design Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg) and left ventricular hypertrophy Atenolol Beta-blocker Dose titrated to BP <140/90 mm Hg (n=4,588) Losartan Angiotensin II antagonist Dose titrated to BP <140/90 mm Hg (n=4,605) Followed for >4 years - Mean follow-up 4.8 years Cardiovascular death, MI, stroke
LIFE: Primary Composite Endpoint Composite of CV Death / MI / Stroke P=0.021 Adjusted Hazard Ratio = 0.87 Rate 23.8/1,000 patient yrs Rate 27.9/1,000 patient yrs n=588 n=508 Losartan Atenolol
LIFE: Individual Endpoint Results Cardiovascular Death Stroke Myocardial Infarction P=0.001 P=0.206 P=0.491 Adjusted HR 0.75 Adjusted HR 0.89 Adjusted HR 1.07 Losartan Atenolol Losartan Losartan Atenolol Atenolol
LIFE: New-onset diabetes P=0.001 Adjusted Hazard Ratio = 0.75 Rate 13.0/1,000 patient yrs Rate 17.4/1,000 patient yrs n=319 n=241 Losartan Atenolol